Literature DB >> 32007524

Emergence of SARS-like coronavirus poses new challenge in China.

Ruichen Wang1, Xu Zhang1, David M Irwin2, Yongyi Shen3.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32007524      PMCID: PMC7126811          DOI: 10.1016/j.jinf.2020.01.017

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


× No keyword cloud information.
Recently, the emergence of African swine fever virus in China has raised great concern in this journal. , The epidemic is not over yet, outbreak of a new SARS-like Coronavirus in Wuhan at the end of 2019 poses new public health challenges in China. Coronaviruses are a large family of viruses that cause respiratory illnesses. Although Coronaviruses (CoVs) have been known for decades, they did not raise great attention in human medicine until the outbreaks of Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). SARS-CoV first emerged in November 2002 in Guangdong province of Southern China and then rapidly spread to 29 countries and regions, infecting over 8000 individuals with a death toll of nearly 800. Ten years after the SARS, MERS emerged in 2012, have caused 2494 human infections with 858 deaths (as of November 2019) and remains a disease of global, and particularly Middle Eastern, public health concern. In 2017, a novel HKU2-related bat coronavirus, swine acute diarrhea syndrome coronavirus (SADS-CoV), caused the death of 24,693 piglets, , raising further concern about these coronavirus. In December 2019, a new coronavirus (2019-nCoV), which is about 70% similar to SARS-Cov, was discovered in the central Chinese city of Wuhan, with 545 cases in 25 provinces being diagnosed (Fig. 1 A, January 22, 2020). According to the World Health Organization (https://www.who.int), in addition to mainland China, this virus has also been detected in Japan, Thailand, Republic of Korea and the United States in travelers from Wuhan. The number of confirmed cases has been gradually increasing (Fig. 1B), which might be partially due to recent the establishment of relevant detection methods, but, at the same time, could signal that there could be a quick expansion of the epidemic.
Fig. 1

The 2019-nCoV epidemic.

(A) Spread of 2019-nCoV in China. Provinces with 545 confirmed 2019-nCoV cases to date (1/22/2020 8:00 PM) are indicated in red (total 25). Provinces in yellow have suspected cases, while those in green have reported no cases. The epidemic is mainly distributed in central and southern China.

(B) Increasing number of cases. The number of confirmed cases by date are plotted, which shows a gradual increase over time.

The 2019-nCoV epidemic. (A) Spread of 2019-nCoV in China. Provinces with 545 confirmed 2019-nCoV cases to date (1/22/2020 8:00 PM) are indicated in red (total 25). Provinces in yellow have suspected cases, while those in green have reported no cases. The epidemic is mainly distributed in central and southern China. (B) Increasing number of cases. The number of confirmed cases by date are plotted, which shows a gradual increase over time. The three basic elements required for an infectious disease epidemic are source of the infection, route of transmission, and susceptible hosts (humans). Eliminating the source of the infection and cutting off the transmission route are usually effective means to block the spread of an infectious diseases. The successful precedent of emergent CoV containment based on the elimination of the primary reservoir is SARS. Bats are suggested to be the reservoir hosts of SARS-CoVs. , However, without an intermediary host, bat derived CoVs cannot directly infect humans. The Carnivora–intermediate amplifying host (civets) of SARS-CoVs was found. The quick control of the intermediate amplifying host by banning wild animal trade was the key factor in the effective control of SARS. Many of the 2019-nCoV infected people had either worked at or frequently visited a seafood market in Wuhan. Apart from fish, the market also sold other live wild animals – sparking concerns that the virus might have been transmitted from an animal to humans, just like SARS and MERS. The Wuhan CoVs cluster with SARS/SARS-like coronaviruses, and have about 70% overall genome sequence similarity. As this virus clusters with various bat Betacoronavirus, it is reasonable to deduce that bats are the native host for the 2019-nCov. However, its origin (source) remains unknown, that is, the animals that are the origin and amplifying hosts for this virus. This makes the elimination of this disease from the source difficult. The control of the route of transmission is another effective means of epidemic control. Infections of healthcare workers and family clusters suggest that 2019-nCoV has the ability to spread from human to human. Although the seafood market has been closed, the number of confirmed cases continues to gradually increase (Fig. 1B). This further supports the conclusion that this virus can spread by human-to-human contact. Previous research has shown that coronaviruses usually have an ability to rapidly mutate. We cannot exclude the possibility that some 2019-nCoVs will mutate to become “super-spreaders”, as seen in SARS. Frequent disinfection of people-intensive places and animal trading markets should help stop the spread of the virus. Unfortunately, the outbreak has cast a shadow over the celebrations for the Lunar New Year, which falls on January 25. Millions of people in China travel over the course of the Spring Festival, both within the country and overseas. In addition, millions of college students (Wuhan has more than 1 million college students) will return to school after the winter vacation. This large-scale population migration could lead to further spread of this virus. Therefore, it is possible that this epidemic will be more serious after the Spring Festival. At present, the National Health Commission of China (http://www.nhc.gov.cn) has listed 2019-nCoV as Class B infectious disease and managed as Class A. Measures including the temperature monitoring of passengers at railway stations, airports, terminals and other transportation hubs have been carried out, which should slow the spread of the virus to a certain extent. However these disease control policies are far from enough, more strict methods to control population flow should be on the table. It is increasingly recognized that a One Health approach at the human–animal–ecosystem interface is needed for effective investigation, prevention and control of any emerging zoonotic disease. In the context of emerging zoonoses, human and veterinary medicine must work together. These viruses emerge from animal trading markets, where veterinary workers need to be vigilant and concerned whether these viruses have the potential to spread between animals and the impact the livestock industry. Veterinary workers should also actively invest in epidemiological investigations to find the natural hosts of these viruses and develop corresponding detection methods. Considering that the original source of the 2019-nCoV is very likely related to a wild animal, additional strict laws to limit wildlife markets should be made, otherwise, more emerging zoonoses from wild animals will occurred in the near future.
  26 in total

1.  Inpatient Care during the COVID-19 Pandemic: A Survey of Italian Physicians.

Authors:  Marina Attanasi; Simone Pasini; Antonio Caronni; Giulia Michela Pellegrino; Paola Faverio; Sabrina Di Pillo; Matteo Maria Cimino; Giuseppe Cipolla; Francesco Chiarelli; Stefano Centanni; Giuseppe Francesco Sferrazza Papa
Journal:  Respiration       Date:  2020-08-05       Impact factor: 3.580

2.  Respiratory sampling for severe acute respiratory syndrome coronavirus 2: An Overview.

Authors:  Anna See; Song Tar Toh
Journal:  Head Neck       Date:  2020-05-08       Impact factor: 3.147

3.  Influenza activity during the outbreak of coronavirus disease 2019 in Chinese mainland.

Authors:  Mi Liu; Lizong Deng; Dayan Wang; Taijiao Jiang
Journal:  Biosaf Health       Date:  2020-09-02

4.  Biosafety and biosecurity approaches to restrain/contain and counter SARS-CoV-2/COVID-19 pandemic: a rapid-review.

Authors:  Tauseef Ahmad; Kuldeep Dhama; Khan Sharun; Fazal Mehmood Khan; Irfan Ahmed; Ruchi Tiwari; Taha Hussien Musa; Muhammad Khan; D Katterine Bonilla-Aldana; Alfonso J Rodriguez-Morales; Jin Hui
Journal:  Turk J Biol       Date:  2020-06-21

Review 5.  Study of combining virtual screening and antiviral treatments of the Sars-CoV-2 (Covid-19).

Authors:  Ehsaneh Khodadadi; Parham Maroufi; Ehsan Khodadadi; Isabella Esposito; Khudaverdi Ganbarov; Silvano Espsoito; Mehdi Yousefi; Elham Zeinalzadeh; Hossein Samadi Kafil
Journal:  Microb Pathog       Date:  2020-05-05       Impact factor: 3.738

Review 6.  Origin, Pathogenesis, Diagnosis and Treatment Options for SARS-CoV-2: A Review.

Authors:  Humna Sajjad; Mohsin Majeed; Saiqa Imtiaz; Mariyam Siddiqah; Anila Sajjad; Misbahud Din; Muhammad Ali
Journal:  Biologia (Bratisl)       Date:  2021-06-02       Impact factor: 1.653

7.  Perceived infection transmission routes, infection control practices, psychosocial changes, and management of COVID-19 infected healthcare workers in a tertiary acute care hospital in Wuhan: a cross-sectional survey.

Authors:  Ying-Hui Jin; Qiao Huang; Yun-Yun Wang; Xian-Tao Zeng; Li-Sha Luo; Zhen-Yu Pan; Yu-Feng Yuan; Zhi-Min Chen; Zhen-Shun Cheng; Xing Huang; Na Wang; Bing-Hui Li; Hao Zi; Ming-Juan Zhao; Lin-Lu Ma; Tong Deng; Ying Wang; Xing-Huan Wang
Journal:  Mil Med Res       Date:  2020-05-11

Review 8.  Clinical and radiological features of novel coronavirus pneumonia.

Authors:  Qiuting Zheng; Yibo Lu; Fleming Lure; Stefan Jaeger; Puxuan Lu
Journal:  J Xray Sci Technol       Date:  2020       Impact factor: 1.535

9.  Emergence of SARS-like coronavirus in China: An update.

Authors:  Zhipeng Zhang; Kangpeng Xiao; Xu Zhang; Ayan Roy; Yongyi Shen
Journal:  J Infect       Date:  2020-03-13       Impact factor: 6.072

10.  Trend and forecasting of the COVID-19 outbreak in China.

Authors:  Qiang Li; Wei Feng; Ying-Hui Quan
Journal:  J Infect       Date:  2020-02-27       Impact factor: 6.072

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.